Format

Send to

Choose Destination
Infection. 2019 May 17. doi: 10.1007/s15010-019-01319-0. [Epub ahead of print]

Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient.

Author information

1
Division of Infectious Diseases and Global Health, University of California, San Diego, 4510 Executive Drive, Suite P7, La Jolla, San Diego, CA, 92121, USA. nalaw@ucsd.edu.
2
Division of Infectious Diseases and Global Health, University of California, San Diego, 4510 Executive Drive, Suite P7, La Jolla, San Diego, CA, 92121, USA.
3
Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, La Jolla, CA, USA.
4
Ampliphi Biosciences Corporation, San Diego, CA, USA.
5
Center for Innovative Phage Applications and Therapeutics, University of California, San Diego, La Jolla, CA, USA.

Abstract

INTRODUCTION:

We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.

HOSPITAL COURSE:

The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later.

CONCLUSION:

Given the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy.

KEYWORDS:

Antibiotic; Antimicrobial; Bacteriophage therapy; Cystic fibrosis; Lung transplant; Multidrug-resistant Pseudomonas aeruginosa

PMID:
31102236
DOI:
10.1007/s15010-019-01319-0

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center